Warfarin Institute of America
DEDICATED TO YOUR HEALTH SINCE 2000
Otamixaban - a Factor Xa Inhibitor being studied as a possible replacement for warfarin
The advantage that is being sought among this class of drugs is lowered bleeding risk compared to warfarin. If this proves true, this class of drugs will be very advantageous.
When otamixaban was administered IV to healthy, male subjects, it was found to have rapid plasma distribution and elimination, low intersubject variability and was excreted by both the liver and the kidney.
References:
Paccaly A et al. Pharmacokinetics of otamixaban, a direct factor Xa inhibitor, in healthy male subjects : Pharmacokinetic model development for phase 2/3 simulation of exposure. J. Clin. Pharmacol. 2006, 46, 37-44
To read about dabigatran, another possible warfarin replacement click here.
To read about ximelagatran, another possible warfarin replacement click here.
To read about rivaroxaban, another possible warfarin replacement, click here.
SEE A CATALOG OF PUBLICATIONS AVAILABLE FROM LODWICK CREATIONS, LLC.
LEARN HOW YOU CAN BECOME LISTED ON THE HONOR ROLL OF SUPPORTERS AND TAKE ADVANTAGE OF THE BENEFITS
REQUEST A MEDICATION CONSULTATION
© 2005 - 2007 Lodwick Creations, LLC
Contact Mr. Lodwick at allodwick@earthlink.net
Last updated April 8, 2007
